What topics does this cannabis study cover?

This study covers research on: THC, CBD, Pain, Sleep, Mental Health.

Cannabis may ease sleep and mood more than nociplastic pain

Q: What did this Review find?

The review included **10 studies**, but most were secondary sources, leaving **limited direct evidence** for cannabis-based medicines in *nociplastic pain*.

Q: Where was this research published?

Published in Journal of pain & palliative care pharmacotherapy on July 22, 2026.

Cannabis-Based Medicines for Nociplastic Pain: A Scoping Review of Efficacy, Safety, and Patient Outcomes.

Journal of pain & palliative care pharmacotherapy • July 22, 2026 • Review • Highly Relevant

🤖

AI Summary

This scoping review examined cannabis-based medicines (CBM) for nociplastic pain—pain linked to altered pain processing rather than ongoing tissue damage. Across 10 studies, the evidence was mostly based on reviews, expert opinions, and consensus documents, with very little direct research connecting CBM to nociplastic mechanisms. The review found signals of modest benefit in conditions such as fibromyalgia and chronic musculoskeletal pain, but improvements appeared more consistent for sleep, mood-related symptoms, and quality of life than for pain relief itself. No quantitative effect estimates were reported in the abstract.

Side effects were common and included sedation, dizziness, and psychiatric symptoms, especially with THC-dominant products. The review also highlighted variable oral absorption, food and liver effects—particularly for CBD—and prolonged drug persistence in the body, along with possible cognitive and psychomotor impairment. For users, the practical message is that benefits may depend on the symptom being targeted, dose, and formulation, while combining CBM with opioids requires caution. Overall, the authors conclude that the evidence is low-certainty and indirect, and that larger, longer studies using standardized pain assessments are needed.

💡 Key Findings

The review included 10 studies, but most were secondary sources, leaving limited direct evidence for cannabis-based medicines in nociplastic pain.

Moderate

50%

CBM showed signals of modest benefits in fibromyalgia and chronic musculoskeletal pain, with improvements more apparent in sleep, affective symptoms, and quality of life than in direct pain relief.

Moderate

50%

Adverse effects—including sedation, dizziness, and psychiatric symptoms—were common, particularly with THC-dominant products.

Good

60%

The overall evidence is low-certainty and indirect; no study used standardized nociplastic pain instruments, and no phenotype-specific opioid-sparing evidence was identified.

Good

70%

📄 Original Abstract

Cannabis-based medicines (CBM) are increasingly considered for nociplastic pain (NOCP) despite limited evidence. This scoping review mapped evidence on efficacy, safety, patient-reported outcomes, and pharmacokinetic/pharmacodynamic (PK/PD) considerations for CBM in NOCP. MEDLINE, Cochrane Library, Web of Science, and Scopus were searched through 2024. Eligibility included patients with NOCP or a nociplastic phenotype, any setting, any study design, and English language. Data were charted inductively, synthesized narratively, and risk of bias was assessed. Ten studies were included, predominantly secondary (reviews/opinions, consensus), with very limited primary data linking CBM to nociplastic mechanisms. Signals suggest modest benefits in fibromyalgia and chronic musculoskeletal pain, with improvements more evident for sleep, affective domains, and quality-of-life than for direct analgesia. Adverse effects were common (e.g., sedation, dizziness, psychiatric symptoms), particularly with tetrahydrocannabinol-dominant products. PK findings included low/variable oral bioavailability (∼6%), food and hepatic effects (notably for cannabidiol), and prolonged terminal half-life; PD effects included psychomotor and cognitive impairment. No study applied standardized nociplastic instruments. Co-administration cautions with opioids were noted, but no phenotype-specific opioid-sparing evidence was identified. Overall, evidence remains low-certainty and indirect, supporting adequately powered, longer-term trials with explicit NOCP phenotyping and standardized formulations. CBM show outcome-specific benefits balanced against dose- and formulation-dependent harms.